Résultats de la recherche
10
Tout
Rechercher les filtres
Organisation
Anavex Life Sciences Corp.
Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference
31 mars 2025 07h30 HE
|
Anavex Life Sciences Corp.
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...
Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference
24 févr. 2025 07h30 HE
|
Anavex Life Sciences Corp.
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...
Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update
12 févr. 2025 07h30 HE
|
Anavex Life Sciences Corp.
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025
05 févr. 2025 07h30 HE
|
Anavex Life Sciences Corp.
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
27 janv. 2025 07h30 HE
|
Anavex Life Sciences Corp.
Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent for Alzheimer's Disease
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease
15 janv. 2025 07h30 HE
|
Anavex Life Sciences Corp.
Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancement Impairment of autophagy precedes both amyloid beta and tau tangles, and...
New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients
13 janv. 2025 07h30 HE
|
Anavex Life Sciences Corp.
Topline ATTENTION-AD trial: Patients showed improved cognition and function over three years Delayed-start analysis of treatment with oral blarcamesine was significant reflecting importance of...
Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
06 janv. 2025 07h30 HE
|
Anavex Life Sciences Corp.
NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update
23 déc. 2024 07h30 HE
|
Anavex Life Sciences Corp.
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease
23 déc. 2024 07h00 HE
|
Anavex Life Sciences Corp.
Blarcamesine: Potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancement Submission based on favorable ANAVEX®2-73-AD-004 trial results in...